Cancer Frontline

February 2018
Archive

Obese patients with metastatic melanoma who are treated with targeted
or immune therapies live significantly longer than those with a normal
body mass index (BMI), investigators report in a study published in
Lancet Oncology of 1,918 patients in six independent clinical cohorts.

This effect, referred to as the “Obesity Paradox”, principally
manifested itself in men, said Jennifer McQuade, M.D., lead author and instructor...

A pair of targeted therapies given before and after surgery for
melanoma produced at least a six-fold increase in time to progression
compared to standard-of-care surgery for patients with stage 3
disease, MD Anderson researchers found in a recent study. Patients who
had no sign of disease at surgery after combination treatment did not
progress to metastasis.

Early results of the study comparing surgery to pre- and post-surgical...